Several studied have recorded an increased incidence of TB in patients with IRD particularly under TNF-inhibitors.3 According to a French prospective study, the annual incidence rate of TB was 9.3 per 100 000 for patients receiving etanercept compared to 187.5 per 100 000 for infliximab, and 215.0 per 100 000 for adalimumab.12 Similarly, another study found that the incidence rate of TB was highest for adalimumab (144/100 000 person-years), followed by infliximab (136/100 000 person-years), and then etanercept (39/100 000 person-years).24 Here, TNF is linked to tuberculosis.